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Abstract
Background:  Parkinson's disease, the most common adult neurodegenerative movement disorder,
demonstrates a brain-wide pathology that begins pre-clinically with alpha-synuclein aggregates ("Lewy
neurites") in processes of gut enteric and vagal motor neurons. Rostral progression into substantia nigra
with death of dopamine neurons produces the motor impairment phenotype that yields a clinical diagnosis.
The vast majority of Parkinson's disease occurs sporadically, and current models of sporadic Parkinson's
disease (sPD) can utilize directly infused or systemic neurotoxins.
Results: We developed a differentiation protocol for human SH-SY5Y neuroblastoma that yielded non-
dividing dopaminergic neural cells with long processes that we then exposed to 50 nM rotenone, a
complex I inhibitor used in Parkinson's disease models. After 21 days of rotenone, ~60% of cells died. Their
processes retracted and accumulated ASYN-(+) and UB-(+) aggregates that blocked organelle transport.
Mitochondrial movement velocities were reduced by 8 days of rotenone and continued to decline over
time. No cytoplasmic inclusions resembling Lewy bodies were observed. Gene microarray analyses
showed that the majority of genes were under-expressed. qPCR analyses of 11 mtDNA-encoded and 10
nDNA-encoded mitochondrial electron transport chain RNAs' relative expressions revealed small
increases in mtDNA-encoded genes and lesser regulation of nDNA-encoded ETC genes.
Conclusion: Subacute rotenone treatment of differentiated SH-SY5Y neuroblastoma cells causes process
retraction and partial death over several weeks, slowed mitochondrial movement in processes and
appears to reproduce the Lewy neuritic changes of early Parkinson's disease pathology but does not cause
Lewy body inclusions. The overall pattern of transcriptional regulation is gene under-expression with
minimal regulation of ETC genes in spite of rotenone's being a complex I toxin. This rotenone-SH-SY5Y
model in a differentiated human neural cell mimics changes of early Parkinson's disease and may be useful
for screening therapeutics for neuroprotection in that disease stage.
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Background
Parkinson's disease (PD) is the most prevalent neurode-
generative movement disorder of adults and occurs spo-
radically in > 90% of cases. While the primary motor
deficits of PD arise from progressive death of dopaminer-
gic substantia nigra neurons, the pathology of PD begins
preclinically in lower brainstem nuclei with the appear-
ance in processes of small α-synuclein (+) aggregates
("Lewy neurites"). The Lewy neurite pathology moves ros-
trally into nigral neurons, followed by death of these neu-
rons, appearance of motor symptoms and formation of
larger intracellular aggregates ("Lewy bodies") in surviv-
ing nigral neurons [1-6]. In later stages, Lewy neurite
pathology appears in limbic and frontal cortex, providing
a substrate for the commonly observed neuropsychologi-
cal clinical problems found in many older PD subjects
[7,8].
A comprehensive understanding of PD pathogenesis must
account for both the widespread nature of its pathology
and the selective vulnerability of nigral dopaminergic
neurons. Contemporary and non-exclusionary hypothe-
ses involve the loss of mitochondrial bioenergetic func-
tion, impairment of proteasomal activity and appearance
of protein aggregates [9-12]. Each of these processes is
potentially neurotoxic, and the combination of oxidative
stress damage, protein aggregation and altered mitochon-
drial function has also been described in vulnerable neu-
rons of Alzheimer's brains [13]. Because mitochondrial
bioenergetic dysfunction and proteasomal impairment
may be interactively linked through oxidative stress,
development of complete PD pathology may require dys-
function of both essential cellular components.
To develop an improved cell model for PD pathology, we
explored different regimens to differentiate SH-SY5Y
dividing neuroblastoma cells into non-dividing differenti-
ated cells that survived for several weeks, formed extensive
processes and exhibited a dopaminergic phenotype. We
exposed these cells to low concentrations of rotenone to
produce ~50% complex I inhibition [14], similar to levels
of complex I deficiency reported in PD brain and tissues.
We report the effects of such rotenone exposure on neuro-
nal survival, protein aggregation and gene expression,
including regulation of mitochondrial electron transport
chain genes, and mitochondrial transport along proc-
esses.
Results
Differentiation and phenotypic analysis
The neuronal phenotype of differentiated SH-SY5Y cells
was confirmed by labeling with antibodies to the neuron
specific beta-tubulin (TUJ1), the 68 kD neurofilament
subunit (NF68) and with the microtubule associated pro-
teins MAP-2 and tau (Figure 1). Both MAP-2 and tau were
uniformly distributed to the cell body and neurites. Tau
was not segregated to the axon-like processes. Synapto-
physin and α-synuclein (αSYN) were also detected by
immunocytochemistry in differentiated SH-SY5Y cells
and exhibited punctuate staining consist with their locali-
Confocal microscopic images of immunohistochemical stain- ing of differentiated SH-SY5Y neural cells following differenti- ation in staurosporine Figure 1
Confocal microscopic images of immunohistochemi-
cal staining of differentiated SH-SY5Y neural cells fol-
lowing differentiation in staurosporine. Abbreviations: 
TUJ1 (Neuronal Class III β-Tubulin); MAP-2 (microtubule 
associated protein 2); NF68 (neurofilament 68); α SYN (α-
synuclein); VMAT (vesicular monoamine transporter) TH 
(tyrosine hydroxylase); DAT (dopamine transporter); D2 
(D2 dopamine receptor); Synap (synaptophysin).Molecular Neurodegeneration 2008, 3:21 http://www.molecularneurodegeneration.com/content/3/1/21
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zation in synaptic vesicles (Figure 1). The dopaminergic
phenotype of differentiated SH-SY5Y cells was confirmed
by immunostaining with tyrosine hydroxylase (TH),
dopamine transporter (DAT), the vesicular monoamine
transporter (VMAT) and the D2 dopamine receptor (D2)
(Figure 1). The dopaminergic markers also exhibited
punctuate staining in the cell body and processes of SH-
SY5Y cells in culture. As part of a separate study we have
also confirmed that staurosporine-differentiated SH-SY5Y
cells express choline acetyltransferase (data not shown),
indicating that these cells continue to express multiple
neurotransmitter types.
Rotenone-induced formation of Lewy neurite-like 
structure
Chronic treatment with 50 nM rotenone induced the for-
mation of neuritic swellings beginning at day 3 and con-
tinuing for up to 20 days. The number of neuritic
swellings per culture was low but they were readily identi-
fiable. Cultures of staurosporine-differentiated, rotenone-
treated SY5Y neural cells were stained with antibodies to
α-synuclein and ubiquitin (Figure 2). These neuritic swell-
ings morphologically resemble the α-synuclein and ubiq-
uitin immunoreactive Lewy neurites seen in increasing
numbers in PD brain samples [1-4]. Neuritic swellings
generated by rotenone exposure also contained concen-
trations of bioenergetically competent mitochondria,
based on their capacity to accumulate the potentiometric
dye MitoTracker CMX-Ros (MtRed) and LysoTracker pos-
itive lysosomes (Figure 2). The dynamic movement of
mitochondria in rotenone-treated neurites exhibiting
neuritic swellings was reduced in comparison with intact
neurites (Figure 3). Reduction in mitochondrial move-
ment was statistically significant by 8 days of rotenone
treatment and was greatest at 16 days, the longest period
studied.
Rotenone-induced cell death
50 nM rotenone produced a biphasic survival curve with
~40% loss by 6 days and a second decline to ~60% loss
between 18 and 21 days (Figure 4). The differentiated cells
surviving in rotenone exhibited progressive loss of proc-
esses (Figure 5). General activation of caspases, moni-
tored with zVAD.fmk-FITC staining, was visible by 2 days
of rotenone at a low level with small intense foci (Figure
6). By 11 days of rotenone more generalized caspase acti-
vation was noted that was still visible at 21 days (Figure
6). We did not observe any evidence for loss of mitochon-




Figure 8 shows a Cluster heatmap for distribution of
expression of named genes across time (days) of rotenone
exposure. The Cluster analysis was performed so that at
least 50% of the samples contained a value. This narrowed
the initial gene list of 10,774 genes present on the array to
1200. The data shown represent the averaged ROT/CTL
ratios from three independent, sequential experiments for
transcripts that reached at least P < 0.05 by the B.A.G.E.L.
algorithm. None of these populations was corrected for
multiple comparisons.
The rotenone-treated, differentiated SH-SY5Y cells had
similar overall patterns of generally reduced expression,
and there were cyclical increases in densities of under-
expressed transcripts at 6d, 13d and 20d of rotenone
exposure. A minority of genes were over-expressed and
showed increased densities at 3d, 6d, 13d and 20d of
rotenone exposure.
qPCR analysis of relative expression of mitochondrial ETC genes
We also determined relative expression levels for mito-
chondrial ETC genes by using qPCR to assay levels of 12
mtDNA-encoded (Figure 9, left) and 10 nDNA-encoded
(Figure 9, right) ETC genes in total RNA's from all three
sets of rotenone-treated and non-treated, differentiated
SH-SY5Y cells. Across the duration of rotenone exposure
there were no substantial changes in expression of
mtDNA-encoded complex I genes, with increases at 6d
and 10d for both ATP synthase genes and an increase for
CO subunit 2 at 6d. The maximum detectable increases in
relative expression for mtDNA-encoded genes ranged
between 1.5–2.2. There were minimal changes in regula-
tion of nDNA-encoded ETC genes.
Discussion
The major conclusion from our study is that it is possible
to create a rotenone-based model of human neuron
degeneration that recapitulates aspects of protein aggrega-
tion and neuritic pathology of early sPD. In our model,
differentiated, non-dividing SH-SY5Y dopaminergic neu-
ral cells experienced gradual death over 3 weeks of expo-
sure to a [rotenone] that produces ~50% inhibition of
complex I activity, comparable to that found in PD brain
and peripheral tissues. Based on preservation of ΔΨM in
surviving cells, we found no evidence of bioenergetic defi-
ciency in terms of potential to synthesize ATP. Although
heterogeneous caspase activation was observed, our meth-
odology does not define which caspase(s) are activated,
and it is presently unknown how this activation occurred
or whether it is causal for the neuronal death that takes
place.
The accumulation of functional mitochondria and lyso-
somes in neuritic swellings suggests that axonal transport
is impaired at these sites. Our studies of mitochondrial
movement in differentiated, rotenone-treated SH-SY5Y
neural cells with neuritic swellings showed that the trans-Molecular Neurodegeneration 2008, 3:21 http://www.molecularneurodegeneration.com/content/3/1/21
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Lewy neurites in processes of differentiated SH-SY5Y neural cells after incubation with 50 nM rotenone for 7 days Figure 2
Lewy neurites in processes of differentiated SH-SY5Y neural cells after incubation with 50 nM rotenone for 7 
days. MtRed = MitoTracker Red; α SYN = alpha synuclein; Phase = phase contrast microscopy; LysoRed = LysoTracker Red.Molecular Neurodegeneration 2008, 3:21 http://www.molecularneurodegeneration.com/content/3/1/21
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port of mitochondria was progressively reduced over the
course of rotenone exposure. Several different mecha-
nisms may contribute to reduced transport in processes
containing neuritic swellings. In addition to binding to
complex I, rotenone also binds to microtubules and dis-
rupts vesicular transport [15]. While this would explain a
total reduction in axonal transport in rotenone-treated
neurons, it would not explain the formation of neuritic
swellings. Rotenone treatment induces oxidative stress,
which has been shown to contribute to axonal swelling
and beading in cultured neurons [15,16]. These authors
suggest that free radical damage can cause focal disruption
of mitotubules and induce the formation of axonal swell-
ings.
Rotenone exposure also elevates the expression of soluble
and insoluble α-synuclein in human neuroblastoma cells
in culture [17]. Over-expression of α-synuclein is detri-
mental to the microtubule system and results in neuritic
degeneration, trafficking defects and Golgi fragmentation
[18]. The formation of α-synuclein aggregates may also
contribute to the generation of neuritic swellings in differ-
entiated, rotenone-treated SH-SY5Y neural cells. In a sim-
ilar vein, huntingtin aggregates can impair mitochondrial
trafficking in cortical neurons [19]. In this study the aggre-
gates blocked the passage of mitochondria in processes
causing them to accumulate adjacent to the aggregates
and become immobile.
The presence of α-synuclein in rotenone-induced neurite
swellings suggests that aggregates of a-synuclein may form
in neurites and impede the movement of mitochondria
and lysosomes. Unlike PD cybrids generated from SH-
SY5Y neuroblastoma cells [20], rotenone-treated, differ-
entiated SH-SY5Y neural cells did not generate cybrid
Lewy bodies. This suggests that rotenone treatment
induces only certain early aspects of PD related patholog-
ical changes that involve protein aggregation.
It is noteworthy that the effects of rotenone exposure on
transcript changes were qualitatively similar across time
with an appearance of cyclical increases in under-expres-
Effects of 50 nM rotenone exposure on mitochondrial movement velocities in processes of differentiated SH-SY5Y neural cells Figure 3
Effects of 50 nM rotenone exposure on mitochondrial movement velocities in processes of differentiated SH-
SY5Y neural cells. The X-axis shows duration of rotenone treatment; Y-axis shows mean +/- SEM mitochondrial movement 
velocities (microns/sec).Molecular Neurodegeneration 2008, 3:21 http://www.molecularneurodegeneration.com/content/3/1/21
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sion and over-expression. These findings suggest that at
the transcriptional regulation level neuronal cell death is
a temporally dynamic process with "waves" of gene
expression changes. However, in our model system the
amplitudes of these changes in gene expression across
rotenone exposure were small and certainly not defining
of a major effect.
A few mitochondrial ETC genes coded for by mtDNA, but
none of the mtDNA-encoded complex I genes, showed
increased expression at 6 and 10 days of rotenone expo-
sure, but ETC genes coded by nuclear DNA, including sev-
eral complex I genes, generally changed very little. Because
rotenone is a complex I toxin, this was a surprising finding
and implies little cellular response to partially impaired
mitochondrial function. Overall, our findings with gene
expression changes suggest that in this model system they
are not likely to provide robust biomarkers for screening
therapeutics.
One important caveat to this study is that although the
SH-SY5Y cells were differentiated to become non-dividing
cells with a neuronal phenotype, they are still derived
from a neuroblastoma tumor lineage and are not primary
neurons. This neoplastic lineage may influence gene
expression responses to subacute rotenone exposure. We
considered using rodent midbrain primary neurons but
decided to stay with the differentiated SH-SY5Y for three
reasons. First, they are human cells, and we felt it was
problematic to compare gene expression responses across
species-specific arrays. Second, they are both the host cells
for our PD cybrids and the cells used in other gene expres-
sion studies, and we wished to be able to compare expres-
sion datasets. Finally, we wanted to develop a rotenone-
based cell culture model for PD with human neural cells,
and the SH-SY5Y line seemed ideal for that purpose. As
differentiated human stem cell-derived dopaminergic
neurons become more widely available, it will be impor-
tant to substitute them for this type of study.
Conclusion
Subacute, low-dose rotenone treatment of differentiated
SH-SY5Y neural cells produced heterogenous caspase acti-
vation, neuritic protein aggregation pathology and proc-
ess retraction that could be considered as similar to that
occurring in early PD. Because we did not have access to
PD brain tissue (esp substantia nigra) from "early" disease
cases, it is not possible for us to compare our gene expres-
sion changes to those of PD nigral neurons at the stage
where neuritic pathology is first appearing. Such a com-
parison would be valuable to determine if our differenti-
ated, rotenone-treated SH-SY5Y neural cell model
recapitulates early gene expression changes of PD nigral
neurons, instead of those found with typical autopsy
material that is from persons with late stage disease. With
that limitation in mind, we suggest that our differentiated
SH-SY5Y neural cells exposed to low [rotenone] are a via-
ble model for pathological changes of early PD and could
be used for screening neuroprotective drugs, particularly
those that might prevent the initial pathologies of process
retraction and Lewy neurite formation. Based on our
results, we do not feel that gene expression changes in this
model are likely to be helpful in therapy development, as
the changes we found were of too low a magnitude to pro-
vide a meaningful signal. However, improvement in
impaired mitochondrial transport may represent a mean-
ingful biological signal to predict reduction of process
retraction and cell death.
Survival of differentiated SH-SY5Y neural cells during expo- sure to 50 nM rotenone Figure 4
Survival of differentiated SH-SY5Y neural cells dur-
ing exposure to 50 nM rotenone. Shown are the means 
+/- SEM's of three independent experiments in which popula-
tion densities of SH-SY5Y cells were determined from count-
ing calcein (+) cells over the course of exposure to 50 nM 
rotenone.Molecular Neurodegeneration 2008, 3:21 http://www.molecularneurodegeneration.com/content/3/1/21
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Methods
General
SH-SY5Y cells were routinely cultured in growth medium
(GM), consisting of high glucose DMEM with 10% FBS,
100 μg/ml pyruvate, 50 μg/ml uridine, and antibiotic-
antimycotic: 100 Units/ml penicillin G, 100μg/ml strep-
tomycin, 0.25 μg/ml amphotericin β. Cells were fed every
2–3 days and passed once a week. Cells were differenti-
ated by culturing in Neurobasal medium and adding stau-
rosporine at 6–10 nM (differentiation medium, DM).
Rotenone treatment
At the end of differentiation, samples were collected for
Day 0 data and medium was changed to begin 50 nM
rotenone treatment on selected flasks and dishes. Both
rotenone and staurosporine were added, fresh, to DM at
each medium change.
Immunocytochemistry and Confocal Microscopy
To immunostain differentiated SH-SY5Y neural cells, cells
were grown in 35 mm glass bottom culture dishes [21],
fixed with 4% paraformaldehyde in 0.1 M phosphate-
buffered saline (PBS), rinsed with PBS and incubated in
blocking solution (0.05% bovine serum albumin and
0.2% triton X-100 in PBS) for 30 min at room tempera-
ture. Then primary antibodies for each antigen were
diluted in PBS containing a 1:10 dilution of blocking
buffer and incubated overnight at 4°C. The primary anti-
bodies used for this study include-α-synuclein (1:500,
AB5038), dopamine transporter (1:1000, MAB369), neu-
rofilament 68 (1:100, AB1983), synaptophysin (1:100,
MAB368), tau (1:100, AB1512), tyrosine hydroxylase
(1:1000, AB151), ubiquitin (1:250, MAB1510) and vesic-
ular monoamine transporter (1:200, AB1767) from
Chemicon International, Inc. (now owned by Millipore,
Temecula, CA). The antibody for the D2DR dopamine
receptor (1:100, sc-9113) was obtained from Santa Cruz
Technology Inc. (Santa Cruz, CA), the microtubule associ-
ated protein 2 was purchased from (MAP-2, 1:62, 13–
1500) Zymed now owned by Invitrogen, (Carlsbad, CA),
and the Neuronal Class III ®-Tubulin was obtained from
Dr. Anthony Frankfurter (University of Virginia). After 3
washes in PBS, the cells were incubated in appropriate flu-
orescein or Texas-red labeled secondary antibodies
Phase contrast images of differentiated SH-SY5Y cells chronically exposed to 50 nM rotenone Figure 5
Phase contrast images of differentiated SH-SY5Y cells chronically exposed to 50 nM rotenone.Molecular Neurodegeneration 2008, 3:21 http://www.molecularneurodegeneration.com/content/3/1/21
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Confocal microscopic images of differentiated SH-SY5Y neural cells exposed to 50 nM rotenone for the indicated number of  days after staining with zVAD.fmk-FITC (green) to indicate activated caspases Figure 6
Confocal microscopic images of differentiated SH-SY5Y neural cells exposed to 50 nM rotenone for the indi-
cated number of days after staining with zVAD.fmk-FITC (green) to indicate activated caspases. Mitochondria 
labeled with MitoTracker Red.Molecular Neurodegeneration 2008, 3:21 http://www.molecularneurodegeneration.com/content/3/1/21
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(1:100, Vector Labs, Burlingame, CA) for 30 min at room
temperature and mounted with Vectashield (Vector Labs,
Burlingame, CA). The fluorescently-labeled anti-rat sec-
ondary antibodies needed to image the dopamine trans-
porter primary antibody were purchased from Jackson
ImmunoResearch Labs, Inc (West Grove, PA). Images of
stained cybrid neurons were created using an Olympus
Fluoview laser scanning confocal microscope system.
To label mitochondria, differentiated cybrid cells were
incubated with 15 nM MitoTracker CMXRos (Invitrogen,
Carlsbad, CA) for 10 min at 37°C. After a brief wash in
Images of JC-1 staining of differentiated SH-SY5Y neural cells  exposed to 50 nM rotenone for the indicated number of days Figure 7
Images of JC-1 staining of differentiated SH-SY5Y 
neural cells exposed to 50 nM rotenone for the indi-
cated number of days. Green corresponds to monomeric 
JC-1 accumulating in low voltage mitochondria, and red cor-
responds to J-aggregates that form in highly energized mito-
chondria. Shown are representative examples of green/red 
image pairs at different rotenone exposure times. Cells with 
loss of red JC-1 aggregate staining were not observed at any 
rotenone exposure time point. Note the absence of neurites 
in the 21 days neurons. CLUSTER heatmap showing distributions of expression  ratios for named genes from differentiated, rotenone-treated  SH-SY5Y neural cells Figure 8
CLUSTER heatmap showing distributions of expres-
sion ratios for named genes from differentiated, 
rotenone-treated SH-SY5Y neural cells. Total RNA 
samples from the three independent rotenone incubation 
experiments were hybridized in duplicate on 19.2K glass 
microarrays. Following analysis for significance with 
B.A.G.E.L. software, the transcripts with P < 0.05 significance 
were annotated with DAVID to named genes and processed 
with CLUSTER to generate the heatmap. Shown are the dis-
tributions of the 1200 genes that were present in at least 
50% of the samples across the time (days) of rotenone expo-
sure. Gray spaces indicate that a particular transcript was not 
present. The colorbar above the heatmap shows the natural 
logarithm of the averaged rotenone/CTL values.Molecular Neurodegeneration 2008, 3:21 http://www.molecularneurodegeneration.com/content/3/1/21
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GM, the cells were imaged using an Olympus IX70
inverted microscope equipped with epifluorescence and
Nomarski optics, a Lambda 10-2 filter wheel, a Photomet-
rics CoolSnap HQ progressive scan CCD camera and Met-
aMorph software (Molecular Devices). Mitochondrial
movement was visualized and quantitated as described
[22]
Confocal microscopic imaging of activated caspases using 
FITC-zVAD.fmk
Differentiated SH-SY5Y cells were grown and treated with
rotenone and staurosporine in 35 mm dishes as described
above. Labeling solutions and labeled cells were protected
from light during the following steps. To label suspended
cells, 40–50 ml of "spent" medium was collected from 20
dishes, centrifuged at 250 × g for 8 min, the pellet was
resuspended in 400 ul Dulbecco's Modified Eagle
Medium with high glucose, HEPES buffer and without
phenol red (Gibco-Invitrogen, Grand Island, NY) and 200
ul plated on the coverslip area of two, 1% porcine skin gel-
atin-coated, 35 mm dishes. After 30 min at 37°C, 100 ul
of HEPES medium containing 30 uM CaspACE FITC-
zVAD-FMK (Promega, Madison, WI) and 240 nM
MitoTracker Red (Molecular Probes, Eugene, OR) was
added and the cells incubated for another 30 min at 37°C.
To label attached cells, maintenance media was removed
and cells incubated for 30 min. at 37°C in HEPES
medium containing 10 uM CaspACE FITC-z VAD-FMK
and 80 nM MitoTracker Red. All labeled dishes were
washed with Hank's Balanced Salt Solution (Gibco-Invit-
rogen, Grand Island, NY), fixed for 20 min in 4% phos-
phate buffered paraformaldehyde with 4% sucrose, pH
7.4, washed with PBS and coversliped using Vectashield
mounting medium (Vector Laboratories, Burlingame,
CA). Single plane confocal images of labeled cells were
collected using an Olympus Confocal Laser Scanning Sys-
tem mounted on an Olympus IX70 microscope.
Microarray studies
We examined gene expression in differentiated SH-SY5Y
after 3, 6, 10, 13, 17 and 20 days of exposure to 50 nM
rotenone. Our approach to microarray studies was to
emphasize both technical and biological replication. To
achieve those goals, we carried out three temporally con-
secutive, independent studies of rotenone exposure. SH-
SY5Y were differentiated as above and then carried for-
ward in culture with or without 50 nM rotenone. At each
time point of rotenone exposure, RNA was harvested from
rotenone-exposed and non-exposed companion cultures.
This procedure attempted to control for any effects of the
differentiation procedure and "aging" in culture, leaving
rotenone exposure as the only variable.
RNA samples were reverse transcribed to fluorescein
labeled (CTL cells) or biotin labeled (ROT cells) cDNA
using the Micromax TSA™ Labeling and Detection Kit
(Perkin Elmer Life and Analytical Sciences, Inc., Waltham,
MA). ROT samples for each time point were each assayed
against the corresponding CTL SH-SY5Y cells.
The two labeled cDNAs were then mixed and hybridized
to a 19.2K human gene array (University Health Network
Microarray Center, Toronto, Ontario) overnight at 40°C
in a humidified chamber. Detection and amplification of
signal were accomplished using a series of antibody-
enzyme conjugates catalyzing the deposition of Cyanine 3
tyramide (Cy3) to CNT or UNT cDNA and Cyanine 5 tyra-
mide (Cy5) to PD or ROT cDNA. Arrays were hybridized
in duplicate and imaged in a scanning confocal slide
reader Scanarray® 4000, (Packard Biochip Technologies,
LLC, Billerica, MA). Random dye-swap experiments with
arrays and labeling reagents from the above manufactur-
ers always produced > 90% concordance for expression
levels.
Statistical processing and gene ontology analysis
Duplicates of background-subtracted, normalized to total
array fluorescence transcript fluorescence ratios (Rot/Ctl)
were first averaged then processed for significance using
B.A.G.E.L. (Bayesian Analysis of Gene Expression Levels,
[23]). The B.A.G.E.L. algorithm makes no assumptions
about what expression levels are "biologically significant"
and instead calculates significance for a given transcript
based on its variance compared to the overall population
variance. In the B.A.G.E.L. analyses performed, all three
independent rotenone experiments at each time point of
rotenone exposure were analyzed together.
We used the B.A.G.E.L. statistical output to devise a liberal
approach to filter transcripts used for subsequent analysis.
To analyze transcript expression patterns, we first col-
lected all transcripts at each rotenone treatment time
point or in the PD brain samples that achieved p < 0.05
significance in the B.A.G.E.L. analysis and were not cor-
rected for multiple comparisons. The GenBank transcripts
were then annotated to gene symbols using D.A.V.I.D.
(Database for Annotation, Visualization and Integrated
Discovery, http://david.abcc.ncifcrf.gov/) and analyzed
using the Cluster [24] algorithm to create visual patterns
of gene changes across time of rotenone exposure com-
pared to those observed in the PD brain samples. We uti-
lized the latest version of Cluster 3.0 to perform
hierarchical clustering and JavaTreeView (v. 1.0.12, http:/
/jtreeview.sourceforge.net) to view the Cluster output.
Real-time, quantitative PCR (RT-qPCR)
Primers for mtDNA and nDNA-encoded ETC genes were
designed with Beacon Designer software and used with
SyberGreen detection to assay relative gene expression in
cDNA's prepared by reverse transcription of the RNA sam-Molecular Neurodegeneration 2008, 3:21 http://www.molecularneurodegeneration.com/content/3/1/21
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ples. All assays were carried out in an iQ5 instrument
(BioRad). Relative gene expression was calculated with
the method of Pfaffl [25].
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